Pains and gains for cancer drugmakers ahead of industry meet
27/05/2022 16:30
(Updates)
** Shares of some cancer drug developers rally while others
trade in red on study data published ahead of key cancer
industry meet
** Shares of Iovance Biotherapeutics IOVA.O plunge over
50%, hitting their lowest since 2017 after company's skin cancer
therapy data disappoints urn:newsml:reuters.com:*:nL3N2XJ1YU
** IOVA is the biggest pct loser on the Nasdaq Biotech index
.NBI and also leads biggest losers across major U.S. exchanges
** SpringWorks Therapeutics SWTX.O second biggest loser on
the biotech index; drops 40% after mixed cancer drug data
urn:newsml:reuters.com:*:nL3N2XJ27M
** Mirati Therapeutics MRTX.O also ends up at the bottom
of the biotech index urn:newsml:reuters.com:*:nL3N2XJ1QA
** Tempest Therapeutics TPST.O , ImmunoGen IMGN.O ,
Elevation Oncology ELEV.O , Harpoon Therapeutics HARP.O among
other cancer drug developers in the red on data to be presented
at the ASCO meet in early June urn:newsml:reuters.com:*:nL3N2XJ1TC
** On the flip side, PMV Pharmaceuticals PMVP.O is the
second biggest pct gainer on the NBI after reporting data on
experimental drug for solid tumors; Oncternal Therapeutics
ONCT.O shares also see boost urn:newsml:reuters.com:*:nGNX7vTvxM urn:newsml:reuters.com:*:nL3N2XJ1OM
** Merus NV MRUS.O also rallies on cancer antibody data;
up more than 20%, on course for biggest intraday pct gain since
October; Adicet Bio ACET.O ticks up on lymphoma therapy data
urn:newsml:reuters.com:*:nL3N2XJ2FD urn:newsml:reuters.com:*:nL3N2XJ1SH
** Exact Sciences EXAS.O and Cullinan Oncology CGEM.O
among other gainers
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))